Histological remission in inflammatory bowel disease and risk of adverse pregnancy outcomes: A nationwide study.
Ustekinumab treatment in ulcerative colitis: Real-world data from the Swedish inflammatory bowel disease quality register.
The Risk of Serious Infections Before and After Anti-TNF Therapy in Inflammatory Bowel Disease: A Retrospective Cohort Study.
Identification of Childhood-Onset Inflammatory Bowel Disease in Swedish Healthcare Registers: A Validation Study.
Association Between Inflammatory Bowel Disease and Spondyloarthritis: Findings from a Nationwide Study in Sweden.
Ustekinumab Is Associated with Real-World Long-Term Effectiveness and Improved Health-Related Quality of Life in Crohn’s Disease.
Prevalence and Implications of Frailty in Older Adults With Incident Inflammatory Bowel Diseases: A Nationwide Cohort Study.
Tumour necrosis factor inhibitors in Crohn’s disease and the effect on surgery rates.
Increased incidence of late-onset inflammatory bowel disease and microscopic colitis after a Cryptosporidium hominisoutbreak.
Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers.
Capturing biologic treatment for IBD in the Swedish Prescribed Drug Register and the Swedish National Patient Register – a validation study.
A Novel Method for Quantifying Intestinal Inflammatory Burden in Inflammatory Bowel Disease Using Register Data.
Healthcare use, work loss and total costs in incident and prevalent Crohn’s disease and ulcerative colitis: results from a nationwide study in Sweden.
The use of ICD codes to identify IBD subtypes and phenotypes of the Montreal classification in the Swedish National Patient Register.
Work Loss in Relation to Pharmacological and Surgical Treatment for Crohn’s Disease: A Population-Based Cohort Study.
Swedish Inflammatory Bowel Disease Register (SWIBREG) – a nationwide quality register.
Work Loss Before and After Diagnosis of Crohn’s Disease.
Validating surgical procedure codes for inflammatory bowel disease in the Swedish National PatientRegister.
Clinical effectiveness of golimumab in Crohn’s disease: an observational study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).
Sick leave and disability pension in prevalent patients with Crohn’s disease.
Incidence and Treatment of Patients Diagnosed With Inflammatory Bowel Diseases at 60 Years or Older in Sweden.
Validating inflammatory bowel disease (IBD) in the Swedish National Patient Register and the Swedish Quality Register for IBD (SWIBREG).
Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)